blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1955709

EP1955709 - Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  18.01.2013
Database last updated on 09.09.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
VICAL INCORPORATED
10390 Pacific Center Court
San Diego, California 92121-4343 / US
[2008/33]
Inventor(s)01 / Wheeler, Carl J.
14101 Arbolitos Drive
Poway, CA 92064 / US
 [2008/33]
Representative(s)Walton, Seán Malcolm, et al
Mewburn Ellis LLP
Aurora Building
Counterslip
Bristol BS1 6BX / GB
[N/P]
Former [2012/11]Walton, Seán Malcolm, et al
Mewburn Ellis LLP 33 Gutter Lane London
EC2V 8AS / GB
Former [2008/33]Walton, Seán Malcolm, et al
Mewburn Ellis LLP York House 23 Kingsway
London WC2B 6HP / GB
Application number, filing date08006254.024.03.2000
[2008/33]
Priority number, dateUS19990126340P26.03.1999         Original published format: US 126340 P
[2008/33]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP1955709
Date:13.08.2008
Language:EN
[2008/33]
Type: A3 Search report 
No.:EP1955709
Date:20.08.2008
[2008/34]
Type: B1 Patent specification 
No.:EP1955709
Date:14.03.2012
Language:EN
[2012/11]
Search report(s)(Supplementary) European search report - dispatched on:EP18.07.2008
ClassificationIPC:A61K39/39, A61K9/127
[2011/39]
CPC:
A61K39/39 (EP,US); A61K31/7088 (EP,US); A61K47/6911 (EP,US);
A61K9/1272 (EP,US); A61P31/00 (EP); A61P31/04 (EP);
A61P31/12 (EP); A61P33/00 (EP); A61P35/00 (EP);
A61P37/04 (EP); A61P37/08 (EP); A61K2039/53 (EP,US);
A61K2039/55511 (EP,US); A61K2039/57 (EP,US); Y02A50/30 (EP,US);
Y10S977/802 (EP,US) (-)
C-Set:
A61K31/7088, A61K2300/00 (EP,US)
Former IPC [2008/33]A61K47/18, A61K39/39, A61P31/04, A61P31/12, A61P33/00, A61P35/00, C07C217/28, // A61P33/00, A61P35/00, C07C217/28
Designated contracting statesAT,   BE,   CH,   CY,   DE,   DK,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [2008/33]
TitleGerman:Adjuvanzverbindungen zur Verbesserung von Immunreaktionen auf Polynukleotid-basierten Impfstoffen[2008/33]
English:Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines[2008/33]
French:Compositions d'adjuvant d'amélioration des réponses immunitaires aux vaccins à base de polynucléotide[2008/33]
Examination procedure31.03.2008Examination requested  [2008/33]
11.03.2009Despatch of a communication from the examining division (Time limit: M06)
29.10.2009Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
06.01.2010Reply to a communication from the examining division
02.07.2010Despatch of a communication from the examining division (Time limit: M04)
14.09.2010Reply to a communication from the examining division
27.10.2011Communication of intention to grant the patent
31.01.2012Fee for grant paid
31.01.2012Fee for publishing/printing paid
Parent application(s)   TooltipEP00919777.3  / EP1165140
EP04014973.4  / EP1459766
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20000919777) is  04.03.2003
Opposition(s)17.12.2012No opposition filed within time limit [2013/08]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
06.01.2010Request for further processing filed
06.01.2010Full payment received (date of receipt of payment)
Request granted
20.01.2010Decision despatched
Fees paidRenewal fee
31.03.2008Renewal fee patent year 03
31.03.2008Renewal fee patent year 04
31.03.2008Renewal fee patent year 05
31.03.2008Renewal fee patent year 06
31.03.2008Renewal fee patent year 07
31.03.2008Renewal fee patent year 08
31.03.2008Renewal fee patent year 09
26.03.2009Renewal fee patent year 10
08.03.2010Renewal fee patent year 11
10.03.2011Renewal fee patent year 12
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT14.03.2012
BE14.03.2012
CY14.03.2012
DK14.03.2012
FI14.03.2012
IT14.03.2012
NL14.03.2012
SE14.03.2012
IE24.03.2012
LU24.03.2012
MC31.03.2012
GR15.06.2012
ES25.06.2012
PT16.07.2012
[2014/27]
Former [2013/22]AT14.03.2012
BE14.03.2012
CY14.03.2012
DK14.03.2012
FI14.03.2012
IT14.03.2012
NL14.03.2012
SE14.03.2012
IE24.03.2012
MC31.03.2012
GR15.06.2012
ES25.06.2012
PT16.07.2012
Former [2013/11]AT14.03.2012
BE14.03.2012
CY14.03.2012
DK14.03.2012
FI14.03.2012
IT14.03.2012
NL14.03.2012
SE14.03.2012
IE24.03.2012
MC31.03.2012
GR15.06.2012
PT16.07.2012
Former [2013/08]AT14.03.2012
BE14.03.2012
CY14.03.2012
DK14.03.2012
FI14.03.2012
NL14.03.2012
SE14.03.2012
IE24.03.2012
MC31.03.2012
GR15.06.2012
PT16.07.2012
Former [2013/07]AT14.03.2012
BE14.03.2012
CY14.03.2012
FI14.03.2012
SE14.03.2012
MC31.03.2012
GR15.06.2012
PT16.07.2012
Former [2013/01]BE14.03.2012
CY14.03.2012
FI14.03.2012
SE14.03.2012
MC31.03.2012
GR15.06.2012
PT16.07.2012
Former [2012/48]BE14.03.2012
CY14.03.2012
FI14.03.2012
SE14.03.2012
MC31.03.2012
GR15.06.2012
Former [2012/47]BE14.03.2012
CY14.03.2012
FI14.03.2012
MC31.03.2012
GR15.06.2012
Former [2012/46]BE14.03.2012
CY14.03.2012
FI14.03.2012
GR15.06.2012
Former [2012/41]CY14.03.2012
FI14.03.2012
GR15.06.2012
Former [2012/37]FI14.03.2012
GR15.06.2012
Former [2012/36]GR15.06.2012
Documents cited:Search[A]WO9719675  (VICAL INC [US]) [A] 1-41 * the whole document *;
 [A]  - NORMAN J A ET AL, "Development of improved vectors for DNA-based immunization and other gene therapy applications", VACCINE, (19970601), vol. 15, no. 8, pages 801 - 803, XP004075655 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0264-410X(96)00247-2
 [A]  - WHEELER C J ET AL, "CONVERTING AN ALCOHOL TO AN AMINE IN A CATIONIC LIPID DRAMATICALLY ALTERS TO CO-LIPID REQUIREMENT, CELLULAR TRANSFECTION ACTIVITY AND THE ULTRASTRUCTURE OF DNA-CYTOFECTIN COMPLEXES", BIOCHIM BIOPHYS ACTA, (1996), vol. 1280, no. 1, pages 1 - 11, XP002035803 [A] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1016/0005-2736(95)00256-1
 [DA]  - WHEELER C J ET AL, "A novel cationic lipid greatly enhances plasmid DNA delivery and expression in mouse lung.", PROC NAT ACAD SCI USA, 1996, (1996), vol. 93, no. 21, pages 11454 - 11459, XP002150135 [DA] 1-41 * the whole document *

DOI:   http://dx.doi.org/10.1073/pnas.93.21.11454
by applicantUS5264618
 WO9429469
 US5580859
 US5589466
 US5676954
 US5693622
 US5703055
    - FEIGNER, SCIENTIFIC AMERICAN, (1997), vol. 276, no. 6, pages 102 - 106
    - FELGNER ET AL., NATURE, (1991), vol. 349, pages 351 - 352
    - ULMER ET AL., CURRENT OPINIONS IN IMMUNOLOGY, (1996), vol. 8, pages 531 - 536
    - BOYER ET AL., J. MED. PRIMATOLOGY, (1996), vol. 25, no. 3, pages 242 - 250
    - BOYER ET AL., NATURE MEDICINE, (1997), vol. 3, no. 5, pages 526 - 532
    - DAVIS ET AL., VACCINE, (1997), vol. 15, no. 8, pages 849 - 852
    - WANG ET AL., VACCINE, (1997), vol. 15, no. 8, pages 821 - 825
    - AGADJANYAN ET AL., CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, (1998), vol. 226, pages 175 - 192
    - HEPPELL ET AL., FISH & SHEDLFISH IMMUNOLOGY, (1998), vol. 8, no. 4, pages 271 - 286
    - LODMELL ET AL., NATURE MEDICINE, (1998), vol. 4, no. 8, pages 949 - 952
    - VANDERZANDEN ET AL., VIROLOGY, (1998), vol. 246, no. 1, pages 134 - 144
    - SASAKI, S. ET AL., INFECTION AND IMMUNITY, (1997), vol. 65, no. 9, pages 3250 - 3258
    - SASAKI, S. ET AL., CLIN, EXP. IMMUNOL., (1998), vol. 111, pages 30 - 35
    - SASAKI, S. ET AL., J. VIROLOGY, (1998), vol. 72, no. 6, pages 4391 - 4939
    - ISHII, N. ET AL., AIDS RES. HUM, RETROVIRUSES, (1997), vol. 13, no. 16, pages 1421 - 1428
    - OKADA, E. ET AL., J. IMMUNOLOGY, (1997), vol. 159, pages 3638 - 3647
    - YOKOYAMA, M. ET AL., FEMS IMMUNOL. MED. MICROBIOL., (1996), vol. 14, pages 221 - 230
    - GREGORIADIS, G. ET AL., FEBS LETTERS, (1997), vol. 402, pages 107 - 110
    - GRAMZINSKI, R.A. ET AL., MOLECULAR MEDICINE, (1998), vol. 4, pages 109 - 118
    - KLAVINSKIS, L.S. ET AL., VACCINE, (1997), vol. 15, no. 8, pages 818 - 820
    - KLAVINSKIS, L.S. ET AL., J. IMMUNOLOGY, (1999), vol. 162, pages 254 - 262
    - ETCHART, N. ET AL., J. GEN. VIROLOGY, (1997), vol. 78, pages 1577 - 1580
    - "Methods in Molecular Medicine", NORMAN, J. ET AL., DNA Vaccines: Methods and Protocols, (1999), vol. 9, pages 185 - 196
    - DNA Vaccines: Methods and Protocols, (1999), vol. 16, pages 185 - 196
    - STEPHAN, D.J. ET AL., HUMAN GENE THERAPY, (1996), vol. 7, pages 1803 - 1812
    - DEBRUYNE, L.A. ET AL., GENE THERAPY, (1998), vol. 5, pages 1079 - 1087
    - FELGNER ET AL., PROC. NATL. ACAD. SCI. USA, (1987), vol. 84, pages 7413 - 7417
    - VAHLSING, H. ET AL., J. IMMUNOL. METHODS, (1994), vol. 171, pages 11 - 22
    - SCHRIJVER, R. ET AL., VACCINE, (1997), vol. 15, pages 1908 - 1916
    - DAVIS, H ET AL., VACCINE, (1994), vol. 12, pages 1503 - 1509
    - GRAMZINSKI, R. ET AL., MOL. MED, (1998), vol. 4, pages 109 - 118
    - QIN ET AL., LIFE SCIENCES, (1999), vol. 65, pages 2193 - 2203
    - WHEELER ET AL., PROC. NATL. ACAD. SCI., (1996), vol. 93, pages 11454 - 11459
    - HARTIKKA, J. ET AL., HUMAN GENE THERAPY, (1996), vol. 7, pages 1205 - 1217
    - VAHLSING, L ET AL., J. IMMUNOL. METHODS, (1994), vol. 174, pages 11 - 22
    - DOH, S,G. ET AL., GENE THERAPY, (1997), vol. 4, no. 7, pages 268 - 263
    - HARTIKKA, J. ET AL., HUMAN GENE THERAPY, (1996), vol. 7, no. 10, pages 1205 - 17
    - HARTIKKA, J. ET AL., HUMAN GENE THERAPY, (1996), vol. 7, pages 1205 - 17
    - HORN, N.A. ET AL., HUMAN GENE THERAPY, (1995), vol. 6, pages 565 - 573
    - ULMER ET AL., SCIENCE, (1993), vol. 259, pages 1745 - 1749
    - SLIFKA, M.K. ET AL., J. VIROL., (1995), vol. 69, no. 3, pages 1895 - 1902
    - SLIFKA, M.K., J. VIROL., (1995), vol. 69, no. 3, pages 1895 - 1902
    - SLIFKA, M.K. ET AL., CURRO OPIN. IMMUNOL, (1998), vol. 10, no. 3, pages 252 - 258
    - HORTON, H.M ET AL., J IMMUNOL., (1999), vol. 163, no. 12, pages 6378 - 6385
    - DOW, S.W. ET AL., Î IMMUNOL., (1999), vol. 163, no. 3, pages 1552 - 1561
    - BEARD, C.W. ET AL., NAT. BIOTECHNOL, (1998), vol. 16, no. 13, pages 1325 - 1328
    - BEARD, C.W. ET AL., NAT. BIOTECHNOL, (1998), vol. 6, no. 13, pages 1325 - 1328
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.